These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14672628)

  • 21. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatorenal syndrome: a comprehensive overview for the critical care nurse.
    Fleming JN; Abou Abbass A
    Crit Care Nurs Clin North Am; 2010 Sep; 22(3):351-68. PubMed ID: 20691386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPSS) and liver transplantation.
    Lerut J; Goffette P; Laterre PF; Donataccio M; Reynaert MS; Otte JB
    Hepatogastroenterology; 1995; 42(6):985-7. PubMed ID: 8847056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hepatorenal syndrome--pathogenesis and clinical aspects].
    Saracyn M
    Pol Arch Med Wewn; 2001 Nov; 106(5):1087-92. PubMed ID: 12026524
    [No Abstract]   [Full Text] [Related]  

  • 25. [Renal insufficiency in liver transplantation].
    Rimola A
    Nefrologia; 2002; 22 Suppl 5():69-71. PubMed ID: 12107922
    [No Abstract]   [Full Text] [Related]  

  • 26. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
    Rice JP; Skagen C; Said A
    Transplantation; 2011 May; 91(10):1141-7. PubMed ID: 21544034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis.
    Cassinello C; Moreno E; Gozalo A; Ortuño B; Cuenca B; Solís-Herruzo JA
    Dig Dis Sci; 2003 Jan; 48(1):179-86. PubMed ID: 12645807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The liver and the kidney: mutual clearance or mixed intoxication.
    Arroyo V
    Contrib Nephrol; 2007; 156():17-23. PubMed ID: 17464111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal dysfunction in cirrhosis.
    Urrunaga NH; Mindikoglu AL; Rockey DC
    Curr Opin Gastroenterol; 2015 May; 31(3):215-23. PubMed ID: 25763790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
    Gülberg V; Bilzer M; Gerbes AL
    Hepatology; 1999 Oct; 30(4):870-5. PubMed ID: 10498636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies.
    Meltzer J; Brentjens TE
    Curr Opin Anaesthesiol; 2010 Apr; 23(2):139-44. PubMed ID: 20124895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vasoconstrictors in the treatment of hepatorenal syndrome].
    Ortega R; Calahorra B; Ginès P
    Nefrologia; 2002; 22 Suppl 5():56-61. PubMed ID: 12107919
    [No Abstract]   [Full Text] [Related]  

  • 33. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Portopulmonary hypertension and hepatorenal syndrome. Two faces of the same coin.
    Zardi EM; Zardi DM; Giorgi C; Chin D; Dobrina A
    Eur J Intern Med; 2017 Sep; 43():22-27. PubMed ID: 28583409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1.
    Sendra C; Silva Ruiz MDP; Ferrer Rios MT; Alarcón García JC; Pascasio Acevedo JM
    Gastroenterol Hepatol; 2018; 41(7):440-441. PubMed ID: 29054321
    [No Abstract]   [Full Text] [Related]  

  • 36. Acute Kidney Injury in Cirrhosis.
    Karvellas CJ; Durand F; Nadim MK
    Crit Care Clin; 2015 Oct; 31(4):737-50. PubMed ID: 26410141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatorenal syndrome: pathophysiology and management.
    Wadei HM; Mai ML; Ahsan N; Gonwa TA
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1066-79. PubMed ID: 17699328
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hepatorenal syndrome].
    Radziszewski A; Sułowicz W
    Przegl Lek; 2006; 63(7):573-8. PubMed ID: 17203812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The reversal of the hepatorenal syndrome in four pediatric patients following successful orthotopic liver transplantation.
    Wood RP; Ellis D; Starzl TE
    Ann Surg; 1987 Apr; 205(4):415-9. PubMed ID: 3551858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.